T. Rowe Price Investment Management Reports New 5.4% Passive Stake in Denali Therapeutics Inc.

T. Rowe Price Investment Management, Inc. has filed a Schedule 13G reporting a new 5.4% stake in Denali Therapeutics Inc. (DNLI). As of March 31, 2026, the investment adviser beneficially owns 8,519,192 shares of common stock. The filing details that T. Rowe Price has sole dispositive power over all 8,519,192 shares and sole voting power over 8,503,878 shares. This position marks a significant increase from zero reported shares in previous filings, crossing the 5% ownership threshold that triggers a Schedule 13G filing. The securities were acquired in the ordinary course of business, indicating a passive investment intent rather than an attempt to influence or change control of the issuer. The filing was officially submitted on May 15, 2026, and confirms the firm's status as a registered investment adviser based in Baltimore, Maryland. Denali Therapeutics is a biopharmaceutical company headquartered in South San Francisco, California.